A Composite Endpoint for Acceptability Evaluation of Oral Drug Formulations in the Pediatric Population.

Wargenau, Manfred; Reidemeister, Sibylle; Klingmann, Ingrid; Klingmann, Viviane

Wargenau, Manfred; Reidemeister, Sibylle; Klingmann, Ingrid; Klingmann, Viviane.

Affiliation

Wargenau M; M.A.R.C.O. GmbH & Co. KG, Institute for Clinical Research and Statistics, Schirmerstrasse 71, 40211, Düsseldorf, Germany.
Reidemeister S; Novartis Pharma AG, Global Drug Development/Technical Research & Development, Novartis Campus, 4056, Basel, Switzerland.
Klingmann I; Pharmaplex bv, Avenue Saint-Hubert 51, 1970, Wezembeek-Oppem, Belgium.
Klingmann V; Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, University Children's Hospital, Heinrich-Heine-University, Moorenstrasse 5, 40225, Düsseldorf, Germany. Viviane.klingmann@med.uni-duesseldorf.de.

Ther Innov Regul Sci ; 56(6): 903-909, 2022 11.

Article de En | MEDLINE | ID: mdl-35471561

Sujet(s)
Mots clés

Acceptability; Oral pediatric formulations; Palatability; Patient centricity; Swallowability

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Préparation de médicament Type d'étude: Clinical_trials Limites: Child / Humans / Newborn Langue: En Journal: Ther Innov Regul Sci Année: 2022 Type de document: Article Pays d'affiliation: Allemagne

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google